Production of Omega-3 Fatty Acids in Rhodococcus Opacus PD630
Total Page:16
File Type:pdf, Size:1020Kb
Production of omega-3 fatty acids in Rhodococcus opacus PD630 Borom Blakie A thesis submitted for the degree of Master of Science at the University of Otago, Dunedin, New Zealand. April 2015 Abstract Omega-3 fatty acids (ω-3 FA) are essential to human health. However, the primary source of ω-3 FA are declining fish stocks. A more sustainable alternative is the cultivation of marine bacteria, however, the yields to date are less than favourable compared with those of fish. Oleaginous bacteria, when genetically engineered with the 16-27 kb pfaA-E gene cluster that encodes ω-3 FA synthesis, may potentially overcome this yield deficiency. One such species is Rhodococcus opacus PD630, which is able to accumulate up to 87% of its cell dry weight as fatty acids. This fatty acid accumulation makes R. opacus PD630 highly desirable as a biotechnological producer strain. However, before ω-3 FA may be produced by genetically engineered R. opacus PD630, work must be undertaken to develop expression vectors carrying the pfaA-E gene cluster. New transformation protocols, capable of handling an expression vector of 30-35 kb, twice the size of the largest reported to have been transformed into a Rhodococcus spp. to date, must also be developed. This thesis describes the development of new protocols, based on electroporation and sonoporation, for the transformation of R. opacus PD630. An electroporation based protocol was successfully developed, with an efficiency of transformation of 5.317 x104 R. opacus PD630 transformants per µg of DNA using the E. coli -Rhodococcus spp. shuttle vector pBS305, compared with 81.15 for the most efficient method previously reported, and 7.158 x106 for Escherichia coli DH5α. A novel method for the generation and recovery of R. opacus PD630 protoplasts for transformation was successfully developed. Protoplast electroporation was found to be ineffective, though protoplasts were able to be used for the extraction of plasmid DNA in the identification of putative transformants. Sonoporation was found to be an ineffective means of transformation, both in E. coli DH5α and R. opacus PD630. ii The development of rhodococcal vectors carrying pfa genes was attempted with LT- PCR from Shewanella baltica chromosomal DNA, and both restriction cloning and PCR of the transgenic expression vector pDHA4. LT-PCR was found to be ineffective at amplifying the 16-20 kb pfa gene cluster of S. baltica, even after optimisation to minimise non-target binding. Restriction cloning of pDHA4 was successful in obtaining the pfa gene cluster, though at a yield insufficient for further use in cloning. PCR amplification of the gene cluster proved to be successful, however, an absence of selective pressure for the gene cluster when inserted into transgenic vectors, and a failure to recover any transformants in E. coli DH5α, meant that this approach was abandoned. PCR amplification of the Rhodococcus spp. gene expression and plasmid maintenance genes from the E. coli -Rhodococcus spp. shuttle vector pTip QT1 was successful. These genes were able to be inserted into pDHA4, although no transformants of E. coli DH5α carrying the construct were able to be recovered. De novo DNA synthesis is a possibility for the construction of the desired transgenic vector. To determine if pDHA4, a purportedly E. coli-only plasmid, could be maintained by R. opacus PD630, a derivative lacking the pfa gene cluster, pDHA4VO, was constructed. Expression of the chloramphenicol resistance gene of pDHA4VO in a confirmed R. opacus PD630 transformant, suggested that R. opacus PD630 was capable of the heterologous expression of DNA from pDHA4. This is the first reported incidence of heterologous expression in R. opacus PD630 without the use of an E. coli -Rhodococcus spp. shuttle vector. Transformation was attempted by electroporation with pDHA4, although no confirmed R. opacus PD630 transformants were recovered. Differences in the GC content between pDHA4 and pDHA4VO are thought to be a contributing factor, and may be indicative of the range of GC contents of DNA which R. opacus PD630 is capable of expressing heterologously. iii Acknowledgements First and foremost, my thanks to my supervisor, Dr. Robin Simmonds, for providing me with the opportunity to undertake this research. His patience and guidance during the course of my study have been invaluable to my development as a scientist. A special thanks to Dr. Felicity McLeod, whose patience and assistance as a post-doctoral fellow were very welcome whilst I settled into research. Thanks also to the other members of the lab: Katie, Chris N. and Chris R., for their advice and commiseration on working with Rhodococcus. I am grateful for the friendships I’ve made in the write-up room, and the support and encouragement that they have fostered. Anthony, Rowan, Maggie, Jonny, Susan, Matt, Manmeet, Sainur, Hoan and Rachel, thanks for the company and the adventures. I extend the same gratitude to the others who have come and gone in my time, and the wider department, listing the names of whom would most probably occupy a document similar in length to this thesis. Thanks to my friends from school, especially Matt, Kurt and Sehan, for encouraging me to undertake an MSc in the first instance, and for supporting me during the course of it. However, I’ll reserve judgment on whether or not to thank the three of you for encouraging me to look into undertaking a PhD. Thanks also to the teachers at Otago Boys’ High School, who taught me the value discipline and hard work, and fostered my burgeoning interest in the biological sciences. Finally, thanks to my parents for their support and assistance in getting this far, and to my siblings, their spouses and children, for all the encouragement and kindness they have shown me. iv Table of Contents Abstract ii Acknowledgements iv List of Abbreviations ix List of Figures xi List of Tables xiii 1. Introduction 1 __1.1. Human health and omega-3 fatty acids 1 __1.2. Sources of ω-3 FA 1 __1.3. Genetic engineering using pfa genes 6 __1.4. Oleaginous bacteria 8 __1.5. PUFA production in R. opacus 9 _____ 1.5.1. Principle 9 _____ 1.5.2. Transformability 10 __1.6. Wider effects of sourcing ω-3 FA from R. opacus 12 __1.7. Hypothesis and study objectives 13 2. Materials and methods 14 __2.1. Stock solutions 14 _____ 2.1.1. General reagents 15 _____ 2.1.2. Antibiotic stock solutions 16 _____ 2.1.3. Media 16 _____ _____2.1.3.1. Growth media 16 _____ __________ _2.1.3.1.1. Commercially sourced media 17 _____ __________ _2.1.3.1.2. Manually prepared media 17 _____ _____2.1.3.2. Transformation media 17 _____ _____2.1.3.3. Freezer stock medium 18 _____ 2.1.4. Protoplasting solutions 18 _____ 2.1.5. Microscope stains 19 _____ 2.1.6. Alkaline lysis reagents 20 _____ 2.1.7. Plasmid preparation buffers 20 _____ 2.1.8. Gel electrophoresis solutions 21 _____ _____2.1.8.1. Gel electrophoresis buffers 21 _____ _____2.1.8.2. Agarose electrophoresis gels 21 _____ _____2.1.8.3. Loading dye 22 __2.2. Bacterial strains, culture conditions and freezer stocks 22 _____ 2.2.1. Bacterial strains and culture conditions 22 _____ 2.2.2. Freezer stocks 25 __2.3. Plasmids 25 __2.4. Microscopy 28 _____ 2.4.1. Light microscopy 28 _____ 2.4.2. Electron microscopy 30 _____ _____2.4.2.1. Transmission electron microscopy 30 _____ _____2.4.2.2. Cryo-transmission electron microscopy 31 v __2.5. Serial dilutions and plating 31 __2.6. Growth and inhibition 32 _____ 2.6.1. Growth curves 32 _____ 2.6.2. R. opacus PD630 morphology during growth 33 _____ 2.6.3. Growth inhibition and function of selective antibiotics 33 _____ _____2.6.3.1. Growth inhibition 33 _____ _____2.6.3.2. Susceptibility to selective antibiotics 35 _____ 2.6.4. R. opacus protoplasts, their viability, and their morphology 35 _____ _____2.6.4.1. Protoplasting 35 _____ ___________ 2.6.4.1.1. Assaf and Dick method 35 _____ ___________ 2.6.4.1.2. Study-generated method 37 _____ _____2.6.4.2. Protoplast viability and morphology 38 __2.7. DNA extractions 38 _____ 2.7.1. E. coli 39 _____ _____2.7.1.1. Commercial DNA extraction kits 39 _____ _____2.7.1.2. Untergasser’s alkaline lysis method 39 _____ 2.7.2. R. opacus PD630 41 _____ _____2.7.2.1. DNeasy pre-treatment for gram positive bacteria 41 _____ _____2.7.2.2. Sambrook and Russell alkaline lysis miniprep 41 _____ 2.7.3. S. baltica 42 _____ 2.7.4. Gel extraction of DNA 43 __2.8. Transformation 43 _____ 2.8.1. E. coli 45 _____ _____2.8.1.1. Preparation of electrocompetent cells and electroporation 45 _________________conditions _____ _____2.8.1.2. Sonoporation 45 _____ 2.8.2. R. opacus 46 _____ _____2.8.2.1. Electrocompetent cell preparation and electroporation - 46 _________________general methods _____ ___________ 2.8.2.1.1. Arenskötter method 46 _____ ___________ 2.8.2.1.2. Desomer method 47 _____ ___________ 2.8.2.1.3. Kalscheuer method 47 _____ ___________ 2.8.2.1.4. Study-generated methods - vegetative cells 47 _____ ___________ ________2.8.2.1.4.1 Optimisation of vegetative cell _____ 48 ___________ ______________________ electroporation _____ ___________ 2.8.2.1.5. Study-generated methods - protoplasts 48 _____ _____2.8.2.2. Sonoporation 48 _____ ___________ 2.8.2.2.1. Optimisation of sonoporation 49 _____ 2.8.3. Calculation of killing rates and efficiency of transformation 49 __2.9.